IP Library Granted Patent US 10,266,487
Granted Patent B2
US 10,266,487 · App. 15/925,559 · Granted Apr 23, 2019

Alpha-cinnamide compounds and compositions as HDAC8 inhibitors

Inventors: Kenneth W. Bair (Wellesley, MA); Nicholas Barczak (Waterford, CT); Bingsong Han (North Haven, CT); David R. Lancia, Jr. (Boston, MA); Cuixian Liu (Madison, CT); Matthew W. Martin (Arlington, MA); Pui Yee Ng (Waltham, MA); Aleksandra Rudnitskaya (Roslindale, MA); Jennifer R. Thomason (Clinton, MA); Mary-Margaret Zablocki (Revere, MA); Xiaozhang Zheng (Lexington, MA)
Assignee: FORMA Therapeutics, Inc.
C07C259/06A61K31/185A61K31/277A61K31/397A61K31/407A61K31/4035A61K31/417A61K31/4184A61K31/435A61K31/438A61K31/44A61K31/4439A61K31/451A61K31/495A61K31/5377C07D207/10C07D207/267C07D209/08C07D209/42C07D209/44C07D209/46C07D211/16C07D211/58C07D213/56C07D213/65C07D213/75C07D213/81C07D215/12C07D221/20C07D231/14C07D231/18C07D233/36C07D233/38C07D233/68C07D235/14C07D235/30C07D239/20C07D239/22C07D241/08C07D241/12C07D249/18C07D257/04C07D261/18C07D277/56C07D295/155C07D295/192C07D307/68C07D317/68C07D333/70C07D401/04C07D401/12C07D401/14C07D405/12C07D409/04C07D409/12C07D417/04C07D417/12C07D471/04C07D471/10C07D487/04C07D487/08C07D487/10C07D491/10C07D493/08C07D495/10C07D498/04C07D513/10Y02A50/393Y02A50/411Y02A50/481
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,266,487
App. No.
15/925,559
Granted
Apr 23, 2019
Kind
B2
Abstract

The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

Claims (61)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

X 1 , X 2 , X 3 , and X 4 are each CH;

R a is hydrogen;

R b is —C(O)R c ;

or alternatively, R a and R b are combined to form a heterocycle, wherein said heterocycle is optionally substituted with one or more R d ;

R c is aryl, optionally substituted with one or more R d or R e ;

R d is hydrogen, C 1 -C 6 alkyl, oxo, C 3 -C 8 cycloalkyl, or —OR e ,

or two R d when attached to the same carbon atom can form a C 3 -C 12 spirocycle or a 3- to 12-membered spiroheterocycle;

R e is aryl; and

A is hydrogen;

with the proviso that:

when R a is H and R b is —C(O)R c , then R c cannot be phenyl, 1-naphthyl, 2-naphthyl, or 4-biphenyl.

2. The compound of claim 1 , wherein R a and R b are combined to form a heterocycle, wherein said heterocycle is optionally substituted with one or more R d .

3. The compound of claim 2 , wherein R d is at least one of hydrogen, C 1 -C 6 alkyl, oxo, or C 3 -C 8 cycloalkyl.

4. The compound of claim 2 , wherein R d is at least one of hydrogen, oxo, C 3 -C 8 cycloalkyl, or two R d when attached to the same carbon atom can form a C 3 -C 12 spirocycle or a 3- to 12-membered spiroheterocycle.

5. The compound of claim 1 , wherein R c is aryl, optionally substituted with one or more R d .

6. The compound of claim 5 , wherein R d is —OR e .

7. The compound of claim 1 , wherein the compound is (E)-N-(2-(3 -(hydroxyamino)-3 -oxoprop-1-en-1-yl)phenyl)-2-phenoxybenzamide.

8. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

9. A composition comprising a compound of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

X 1 , X 2 , X 3 , and X 4 are each CH;

R a is hydrogen;

R b is —C(O)R c ;

or alternatively, R a and R b are combined to form a heterocycle, wherein said heterocycle is optionally substituted with one or more R d ;

R c is aryl, optionally substituted with one or more R d or R e ;

R d is hydrogen, C 1 -C 6 alkyl, oxo, C 3 -C 8 cycloalkyl, or —OR e ,

or two R d when attached to the same carbon atom can form a C 3 -C 12 spirocycle or a 3- to 12-membered spiroheterocycle;

R e is aryl; and

A is hydrogen;

with the proviso that:

when R a is H and R b is —C(O)R c , then R c cannot be phenyl, 1-naphthyl, 2-naphthyl, or 4-biphenyl; and

wherein the compound is obtained by a process comprising a step of treating a compound 2:

with hydroxylamine and sodium hydroxide to form the compound of Formula I.

10. The composition of claim 9 , wherein the process further comprises a step of treating a compound 1:

wherein Hal is halogen,

with an amine under palladium- or copper-mediated cross-coupling conditions to form the compound 2:

11. The composition of claim 9 , wherein the process further comprises a step of treating a compound 4:

with a carboxylic acid to form the compound 2:

12. A composition comprising a compound of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

X 1 , X 2 , X 3 , and X 4 are each CH;

R a is hydrogen;

R b is —C(O)R c ;

or alternatively, R a and R b are combined to form a heterocycle, wherein said heterocycle is optionally substituted with one or more R d ;

R c is aryl, optionally substituted with one or more R d or R e ;

R d is hydrogen, C 1 -C 6 alkyl, oxo, C 3 -C 8 cycloalkyl, or —OR e ,

or two R d when attached to the same carbon atom can form a C 3 -C 12 spirocycle or a 3- to 12-membered spiroheterocycle;

R e is aryl; and

A is hydrogen;

with the proviso that:

when R a is H and R b is —C(O)R c , then R c cannot be phenyl, 1-naphthyl, 2-naphthyl, or 4-biphenyl; and

a compound 2:

13. The composition of claim 12 , wherein R a and R b are combined to form a heterocycle, wherein said heterocycle is optionally substituted with one or more R d .

14. The composition of claim 13 , wherein R d is at least one of hydrogen, C 1 -C 6 alkyl, oxo, C 3 -C 8 cycloalkyl, or two R d when attached to the same carbon atom can form a C 3 -C 12 spirocycle or a 3- to 12-membered spiroheterocycle.

15. The composition of claim 12 , wherein R c is aryl optionally substituted with —OR e .

16. The composition of claim 12 , wherein the compound of Formula I is (E)-N-(2-(3-(hydroxyamino)-3-oxoprop-1-en-l-yl)phenyl)-2-phenoxybenzamide.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 17, 2023
From: FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT
To: VALO HEALTH, INC.; VALO HEALTH, LLC
Reel/Frame 065255/0660 →
SECURITY INTEREST Recorded Jul 6, 2023
From: VALO HEALTH, LLC; VALO HEALTH, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT
Reel/Frame 064207/0957 →
MERGER Recorded Sep 8, 2021
From: VALO EARLY DISCOVERY, INC.
To: VALO HEALTH, INC.
Reel/Frame 057438/0025 →
CHANGE OF NAME Recorded Sep 16, 2020
From: INTEGRAL EARLY DISCOVERY, INC.
To: VALO EARLY DISCOVERY, INC.
Reel/Frame 053787/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2020
From: FORMA THERAPEUTICS, INC.
To: INTEGRAL EARLY DISCOVERY, INC.
Reel/Frame 053402/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2018
From: BAIR, KENNETH W.; BARCZAK, NICHOLAS; HAN, BINGSONG; LANCIA, DAVID R., JR.; LIU, CUIXIAN; MARTIN, MATTHEW W.; NG, PUI YEE; RUDNITSKAYA, ALEKSANDRA; THOMASON, JENNIFER R.; ZABLOCKI, MARY MARGARET; ZHENG, XIAOZHANG
To: FORMA THERAPEUTICS, INC.
Reel/Frame 046303/0823 →
Continuity (6)
Continuation 15688732 · Aug 28, 2017
Continuation 15067605 · Mar 11, 2016
Provisional Application 62270371 · Dec 21, 2015
Provisional Application 62184335 · Jun 25, 2015
Provisional Application 62132895 · Mar 13, 2015
Related Publication 20180297939A1 · Oct 18, 2018